Typical clinical uses
- Clinical chemistry, hematology, and immunoassay analyzers
- Molecular diagnostics and PCR platforms
- Point-of-care IVD devices (POC)
- Companion diagnostics tied to therapeutics
- LIS / LIMS middleware and lab-automation orchestration
Cybersecurity for IVD analyzers, LIS integrations, and lab platforms.
IVD analyzers are connected lab instruments that integrate with LIS, middleware, and increasingly cloud reporting. We secure the LIS interface, instrument OS, and remote service paths against both unauthenticated network attacks and insider misuse.
Connected IVD analyzers and middleware sit between lab samples, LIS systems, and increasingly the cloud. A result-tampering compromise is a direct patient-safety event, and lab protocols (HL7, ASTM) often have no native authentication - the design must compensate at the network and middleware layers.
Cloud connectivity changes the risk class of a previously offline IVD for both FDA and customers - it is not just a back-end change.
Typical clinical uses
Key data flows & integrations
Lab interface parsers are a chronic source of memory-safety and authorization bugs.
Many analyzers run end-of-life OS images - patching, allowlisting, and segmentation must be documented.
Vendor remote support paths must be MFA-protected and session-logged.
Lab analyzers and IVD instruments combine a Windows-based control PC with internal robotics on a CAN or proprietary bus, plus an LIS / middleware integration that crosses the hospital network.
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
IVD analyzer ecosystems sit between sample, LIS/middleware, and (increasingly) the cloud. The cybersecurity history is concentrated on lab interfaces, embedded Windows hosts, and vendor remote service.
Historical incidents
BD disclosed that certain Pyxis products were affected by the Log4j (Log4Shell) vulnerability, illustrating how a single dependency in a clinical platform can propagate immediate cyber risk to deployed lab and pharmacy environments.
BD Product Security Bulletin, Dec 2021
The Ripple20 (Treck TCP/IP, 2020) and URGENT/11 (VxWorks, 2019) advisories affected widely embedded network stacks used across lab analyzers, middleware appliances, and bedside diagnostic devices. FDA directed manufacturers to assess and disclose exposure across categories.
CISA ICSMA-20-168-01 (Ripple20)CISA ICSMA-19-274-01 (URGENT/11)
The HL7 v2 and ASTM lab-interface protocols have no native authentication. Documented incidents of result-tampering have been demonstrated in research settings, and reviewers expect compensating controls at the network and middleware layers.
Active threat scenarios
Without integrity protection or out-of-band verification, modified results can flow into the EHR.
Shared or weakly scoped service accounts expand blast radius from a single host compromise.
Vendor support tunnels are a frequent entry point - they must be modeled as production interfaces.
End-of-life Windows hosts with allowlisting gaps are a recurring procurement blocker for connected analyzers.
What FDA reviewers cite
Connected IVD analyzers and middleware sit between lab samples, LIS systems, and (increasingly) the cloud - a result-tampering compromise is a direct patient-safety event.
Lab protocols often have no native authentication - your design must compensate at the network and middleware layers.
Service-engineer tooling is a recurring entry point and must be treated as a production interface in the threat model.
Adding cloud connectivity to a previously offline IVD changes its risk class for both FDA and customers.
Cross-border lab networks bring GDPR, HIPAA, and local data-residency obligations into your cloud architecture.
What FDA scrutinizes
Reviewers want explicit modeling of analyzer → LIS → EHR with integrity controls at each hop.
Adding cloud changes the risk profile and the cyber documentation expected.
Counterfeit and tampered consumables are an emerging concern - identity authentication should be in the threat model.
Standards & deliverables
Six deliverables FDA and notified bodies expect across MedTech, with the ivd-specific wrinkle on each row. Use it as a scoping checklist before you brief vendors or your QA team.
Machine-readable SBOM (CycloneDX/SPDX) plus VEX feed for every CVE that touches a listed component.
Continuous CVE / advisory monitoring against the SBOM, with a documented triage and disclosure path.
Black/grey-box testing across device, wireless interfaces, mobile apps, cloud APIs, and service tooling.
STRIDE-per-interface threat model with documented mitigations and residual-risk acceptance.
Signed firmware/software updates with rollback protection, integrity verification, and staged rollout.
Public CVD policy, intake channel, and SLAs for triage, fix, and customer communication.
No - they run in parallel. CLIA governs lab operations and personnel; FDA cybersecurity expectations apply to the IVD device or system as a regulated product. Both apply, and the documentation must be coherent across them: an analyzer's secure-update story, for example, has to make sense to both an FDA reviewer and a CLIA-regulated lab director.
End-of-life Windows is the IVD industry's biggest open cyber finding. We document compensating controls in the SPDF and labeling - segmentation, application allowlisting, restricted services, hardened user accounts, time-bounded service access - and we test the resulting attack surface from both authenticated and unauthenticated positions on the lab network. The submission also includes a documented OS migration plan so reviewers see the trajectory, not just the snapshot.
Every middleware and LIS interface in scope is enumerated with its protocol, authentication mechanism, and parser. We fuzz the parsers (ASTM E1394 in particular has a thin error-handling history), test authentication and authorization on every message type, and verify behavior under malformed and oversized payloads. Findings are tied back to specific message types so QA and dev know exactly what to remediate.
Yes - vendor remote support paths are one of the most consistently scrutinized cyber surfaces on IVDs because they are high-privilege, often persistent, and outside lab change control. We require and validate MFA, jump-host isolation between the public internet and the analyzer, full session recording with tamper-evident storage, least-privilege scoping, and time-bounded access tokens, and we pen-test the path end-to-end including credential handling on the vendor side.
If you ship or recommend middleware as part of the cleared system, it's in scope. We test it the same way as the analyzer - application security, authentication, integration security, audit logging - and we make sure the SBOM, threat model, and labeling treat it as part of the regulated product. If middleware is genuinely third-party and out of scope, the boundary is documented explicitly so reviewers don't infer otherwise.
A formal postmarket cybersecurity management plan: SBOM monitoring across analyzer OS, instrument firmware, middleware, and any cloud components; a Coordinated Vulnerability Disclosure (CVD) program with published intake and severity-based SLAs; a controlled patch and update plan that respects clinical-lab uptime constraints; and integration of CVE triage into your QMS so each finding maps cleanly to a controlled change.
Point-of-care and near-patient IVDs (cartridge-based molecular, POC chemistry, rapid antigen with connectivity) often connect over Wi-Fi/cellular and integrate directly with EHRs, so the cloud and EHR boundaries get more weight in the threat model. Core-lab analyzers are usually in a hospital LAN sub-network, where service tunnels and middleware are the dominant threats. The same standards apply, but the test plan is tuned to the actual deployment topology.
Yes. CDx and assay-reporting software are in scope as connected components, often with SaMD characteristics. We test the data path from instrument to result to clinician/EHR, verify integrity of the reported result, and audit the change-control story for the assay's software and decision rules. Where AI/ML is in the result chain, supply-chain controls and any PCCP cyber elements are documented in the SPDF.
Reagent and cartridge identification (RFID, barcode, vendor-proprietary) is exercised for spoofing, replay, and counterfeit-consumable acceptance, since accepting a non-genuine consumable is both a clinical and a business-model issue. The SPDF documents the integrity controls and the threat model traces them back to specific patient-impact scenarios.
Typical baseline: FDA 2026 final premarket cybersecurity guidance, AAMI SW96, AAMI TIR57, IEC 62304, ISO 14971, ISO 13485, IEC 81001-5-1 for the secure software lifecycle, plus IEC 61010 for the instrument and CLSI standards where applicable. EU manufacturers operating under IVDR add Annex I requirements and MDCG guidance; we map artifacts across both regimes.
For a connected core-lab analyzer with middleware and LIS integration, end-to-end premarket cyber work generally runs 8-14 weeks. POC molecular or rapid devices with cloud and EHR integration typically run 6-10 weeks. Threat modeling and SBOM front-load, pen testing across analyzer/middleware/integrations runs in the middle weeks, and the consolidated submission package and postmarket plan close out at the end - all under a written deficiency commitment.
LIS/HL7 interface testing, instrument firmware review, and SBOM for IVD analyzers and molecular platforms.
"Blue Goat Cyber's depth of expertise was impressive. We had no in-house cybersecurity experience, and their team guided us through every step of the FDA process. The penetration testing and SBOM testing were thorough and gave us complete confidence."
Cybersecurity for IVD analyzers, LIS integrations, and lab platforms.
